RP-HPLC Method for Simultaneous Estimation of Omeprazole and Ondansetron in Combined Dosage Forms

A RP-HPLC method is developed for simultaneous estimation of omeprazole and ondansetron in combined tablet dosage form. Omeprazole is a proton pump inhibitor and in the treatment of gastro-oesophageal reflux disease (GERD), peptic ulcer and Zollinger-Ellison syndrome. Ondansetron is used as selective 5-HT3 receptor antagonist and used in the management of nausea and vomiting induced by cytotoxic chemotherapy and radio therapy and also post operative nausea and vomiting. The mobile phase used was a combination of Methanol: Acetonitrile (90:10). The detection of the combined dosage form was carried out at 218 nm and a flow rate employed was 0.5 ml/min. The retention time for omeprazole and ondansetron was found to be 5.39 and 11.08 min respectively. Linearity was obtained in the concentration range of 4 to 20 μg/ml of omeprazole and 4 to20 μg/ml of ondansetron with a correlation coefficient of 0.997 and 0.9967. Detector consists of photodiode array detector; the reversed phase column used was RP-C18 (2.27μm size, 250 mm´4.6 mm i.d.) at ambient temperature. The developed method was validated according to ICH guidelines and values of accuracy, precision and other statistical analysis were found to be in good accordance with the prescribed values. Thus the proposed method was successfully applied for simultaneous determination of ondansetron and omeprazole in routine analysis.